In Case You Missed It: Three Things we Learned in our Dealmaking Trends Webinar
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore is dealmaking trends – and that’s just what my colleagues Ben Folwell and Duncan Sweeney did during our recent webinar, “Licence Drivers: Trends in Pharma […]
2024 Dealmaking: What’s the Score?
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […]
In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re back, though, you’ll be delighted to know that it’s available on demand so you can catch up at your leisure. Our panel, which included Daniel […]
Unlocking the Power of AI in Pharmaceutical Forecasting
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by next year and AI’s impact on new drug development is expected to grow 40% annually. There is no part of the pharmaceutical ecosystem that isn’t […]
In Case You Missed It: Three Things we Learned in our World Preview Webinar
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of the future of this ever-changing market, from the biggest drugs and players, to the therapy areas in growth or decline. The report is excellent (not […]
Who’s winning in the battle for efficient capital deployment?
Over the last ten years, large pharma companies have spent an average of $120bn across R&D and business development investments. The net result? Portfolios worth approximately $210bn, according to Evaluate’s net present value (NPV) methodology. However, within these averages lie dramatically diverging performances, highlighting the challenges of deploying capital efficiently. Overall company performance is heavily […]
What’s Behind Pharma’s Growth Boost?
One of the milestones in the Evaluate year is the publication of our annual World Preview report, now in its 17th year. If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed […]
